A DRIVEN DEVELOPER OF ‘PASSIVELY SMART’ SPINAL IMPLANT SYSTEMS
Founded in 2009, Cutting Edge Spine’s mission is to develop and commercialize transformational orthopedic fixation systems that are ‘passively smart’ in nature and focused upon real improvement in clinical outcomes associated with orthopedic fixation while at the same time respecting the fiscal value concerns of the marketplace.
The First In The Industry
Cutting Edge Spine has demonstrated its commitment to the development and commercialization of futuristic spinal technologies in pursuit of better patient care outcomes having been ‘first to market’ in the U.S with several bio-active materials in addition to novel fixation that potentially provide better early onset bone apposition to implants.
EXTENSIVE TRABECULAR TECHNOLOGY PATENT PORTFOLIO
Cutting Edge Spine has attained an extreme position of strength relative to the granting of an extensive patent portfolio for trabecular fixation relative to all orthopedic applications. Leveraging this strong patent position, combined with the vast company acuity
that comes from Cutting Edge Spine being the first to market with novel bio-active materials, affords Cutting Edge Spine a very unique position both today and forgoing.
TRANSFORMATIONAL, EFFECTIVE, AND SAFE
To stay on the cutting edge of spinal innovation, CES reinvests a substantial percentage of its annual revenues back into the research and development of new innovative technologies.
Quality and risk management are a key ingredients of the Cutting Edge Spine value proposition. Our relentless commitment and continuous progression of our quality system is unparalleled as we use validated production processes that ensure first-in-class quality.
The collection of clinical data is at the core of CES’s mission to provide better spinal technologies geared towards better clinical outcomes.
OUR LATEST INFORMATION
Information From Our Latest Press Releases
Cutting Edge Spine Announces Notice of Issuance from the U.S. Patent and Trademark Office regarding Patent No. US 10,993,754 B2: IMPLANTS FOR TISSUE FIXATION AND FUSION
Cutting Edge Spine Announces FDA 510(K) Clearance of its New HA Enhanced PEEK Interbody System for a Direct Lateral Approach to the Spine, the EVOL®ha-DLIF
Randy Roof – President & CEO; Founder